Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) granted an aggregate of 12,990 RSUs to two newly hired non-executive employees effective March 1, 2026, under the company’s 2025 Inducement Equity Plan.

Grants were approved by the Compensation Committee per Nasdaq Listing Rule 5635(c)(4). Vesting: 25% on the one-year anniversary, then 6.25% quarterly on March 1, June 1, September 1 and December 1 thereafter, subject to continuous service and award agreements.

Key Figures

Inducement RSUs granted: 12,990 RSUs Initial vesting portion: 25% Ongoing vesting rate: 6.25% quarterly +5 more

8 metrics

Inducement RSUs granted 12,990 RSUs Aggregate grant to two new non-executive employees effective Mar 1, 2026

Initial vesting portion 25% One-fourth of RSUs vest on first anniversary of vesting commencement

Ongoing vesting rate 6.25% quarterly Portion of RSUs vesting each quarter after first anniversary

Quarterly vesting dates Mar 1, Jun 1, Sep 1, Dec 1 Recurring vesting dates each year, subject to continued service

Shelf registration capacity $400,000,000 Form S-3 shelf filed Nov 6, 2025 for multiple security types

ATM program size $150,000,000 ATM common stock program included within S-3 shelf aggregate

1-day price change -6.72% Move on latest trading day before this news release

52-week range $4.93–$12.93 Current price of $11.68 is 9.67% below 52-week high

Market Reality Check

Price: $11.93 Vol: Volume 284,794 is above t...

normal vol

$11.93 Last Close

Volume Volume 284,794 is above the 20-day average of 192,543, indicating elevated trading activity ahead of this filing. normal

Technical Shares at $11.68 are trading above the 200-day moving average of $7.99 and about 9.67% below the 52-week high of $12.93.

Peers on Argus

TRDA fell 6.72% while several biotech peers were positive, including CCCC (+21.4...

2 Up 1 Down

TRDA fell 6.72% while several biotech peers were positive, including CCCC (+21.46%), TLSA (+7.97%), EPRX (+3.11%), and TNYA (+2.37%). Momentum data also show EPRX and CGTX up, highlighting TRDA’s stock-specific weakness versus a generally firm peer group.

Common Catalyst Peer news centered on conferences and pipeline updates, while TRDA’s item was a routine inducement equity grant.

Historical Context

5 past events · Latest: Feb 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Earnings and pipeline	Neutral	+6.8%	Q4 and 2025 results plus DMD pipeline and cash runway update.
Feb 17	Clinical trial update	Positive	+1.3%	DMC backed dose escalation to 12 mg/kg in ELEVATE-44-201 Cohort 2.
Feb 04	Investor conferences	Neutral	-8.2%	Planned CEO fireside chats at two investor healthcare conferences.
Jan 08	Pipeline progress	Positive	-2.1%	Broad neuromuscular and ocular pipeline update with multiple 2026 readouts.
Dec 17	Conference presentation	Neutral	-1.3%	Announcement of presentation at the J.P. Morgan Healthcare Conference.

Pattern Detected

Recent news has usually led to price moves consistent with the tone of the announcements, with one notable selloff on a broadly positive pipeline update.

Recent Company History

Over the last few months, TRDA has highlighted steady clinical and corporate progress. On Feb 26, 2026, Q4 and full‑year 2025 results plus pipeline updates coincided with a +6.76% move. A positive DMC recommendation for ELEVATE‑44‑201 on Feb 17, 2026 saw a smaller gain of 1.29%. Earlier portfolio and conference updates in January–February 2026 triggered modest declines. Against this backdrop, the current inducement RSU grants appear routine relative to prior, more substantive catalysts.

Regulatory & Risk Context

Active S-3 Shelf · $400,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-06

$400,000,000 registered capacity

The company has an active Form S-3 shelf filed on Nov 6, 2025 to offer up to $400,000,000 of securities, including a $150,000,000 ATM program for common stock, with no usage recorded to date and the registration not yet effective.

Market Pulse Summary

This announcement details routine equity compensation: an aggregate 12,990 RSUs granted to two new n...

Analysis

This announcement details routine equity compensation: an aggregate 12,990 RSUs granted to two new non‑executive employees under the 2025 Inducement Equity Plan, vesting over time subject to continued service. In recent months, more material catalysts have included earnings, DMD trial updates, and broader pipeline progress. Investors following the story may focus more on upcoming ELEVATE‑44‑201 data and the company’s S‑3 capacity of up to $400,000,000 for future financing flexibility than on this administrative grant.

Key Terms

restricted stock units, rsus, inducement equity plan, nasdaq listing rule 5635(c)(4)

4 terms

restricted stock units financial

"the Company granted an aggregate of 12,990 restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"12,990 restricted stock units (“RSUs”) to two newly-hired non-executive employees"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

inducement equity plan financial

"under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”)"

An inducement equity plan is a program that offers employees or executives new stock options or shares as a way to encourage them to join or stay with a company. It acts like a reward or incentive to motivate performance and loyalty, aligning their interests with the company's success. For investors, such plans can influence a company's share structure and future earnings, making them an important factor to consider.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of March 1, 2026. The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest quarterly thereafter on each subsequent vesting date, with such vesting dates of March 1, June 1, September 1 and December 1 of each subsequent year, in each case, subject to each employee’s continuous service with the Company through each vesting date. The RSUs are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2025 and the terms and conditions of award agreements covering the grants.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Investor Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com

FAQ

What RSUs did Entrada Therapeutics (TRDA) grant on March 1, 2026?

Entrada granted an aggregate 12,990 restricted stock units to two new non-executive employees. According to the company, the awards were made under its 2025 Inducement Equity Plan and approved by the Compensation Committee per Nasdaq rules.

How does the vesting schedule for TRDA inducement RSUs work?

The RSUs vest 25% after one year, then 6.25% quarterly thereafter. According to the company, subsequent vesting dates are March 1, June 1, September 1 and December 1, subject to continuous service and award agreement terms.

Why did Entrada Therapeutics (TRDA) issue inducement grants under Nasdaq Rule 5635(c)(4)?

The grants served as material inducements to new hires to enter employment with the company. According to the company, the Compensation Committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4).

Are the March 1, 2026 RSU grants for TRDA subject to any plan terms?

Yes, the RSUs are subject to the company’s 2025 Inducement Equity Plan and individual award agreements. According to the company, vesting and other terms follow those approved by the board in March 2025.

How many employees received inducement RSUs from Entrada (TRDA) on March 1, 2026?

Two newly hired non-executive employees received the aggregate award of 12,990 RSUs. According to the company, the grants were effective March 1, 2026 and approved by the Compensation Committee.

What conditions could prevent the TRDA RSUs from vesting as scheduled?

RSU vesting is conditioned on each employee’s continuous service through each vesting date and compliance with award agreements. According to the company, failure to meet those conditions would delay or forfeit vesting.